TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01849978

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Newsletter about physical activity and breast cancer survivors
Description: Both groups will receive a newsletter that covers: 1) the recommendation to pursue at least 150 mins/week of moderate to strenuous intensity PA, 2) the benefits of PA specific to breast cancer survivors (e.g., reducing in death and breast cancer recurrence), and 3) their total minutes of moderate to strenuous intensity PA and how this compares to the recommendation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Newsletter about physical activity and breast cancer survivors
Description: Both groups will receive a newsletter that covers: 1) the recommendation to pursue at least 150 mins/week of moderate to strenuous intensity PA, 2) the benefits of PA specific to breast cancer survivors (e.g., reducing in death and breast cancer recurrence), and 3) their total minutes of moderate to strenuous intensity PA and how this compares to the recommendation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Changing your habits brochure
Description: Both groups will receive the brochure titled Changing Your Habits: Steps to Better Health, developed by the NIH, that describes, based a person's stage of change, the benefits of PA, how to overcome common barriers to PA, and if ready, how to plan for PA.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Changing your habits brochure
Description: Both groups will receive the brochure titled Changing Your Habits: Steps to Better Health, developed by the NIH, that describes, based a person's stage of change, the benefits of PA, how to overcome common barriers to PA, and if ready, how to plan for PA.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tips for making exercise enjoyable and personally-valued
Description: Participants will get a list of potentially enjoyable activities and a space to list other activities after they consider aspects that can make events fun/interesting.13 Aspects to consider include: location (indoors vs. outdoors, the latter which may appeal to some), hobbies that can involve PA (e.g., sports, dancing), whether the activity is made more enjoyable by having it performed by oneself or with others (e.g., team activities vs. individual activities); what valued outcomes may be achieved (e.g., sense of competence, pride, better health, body image), accompanying activities that are pleasant (e.g., listening to music), etc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Testimonials from breast cancer survivors
Description: Participants will get two to three testimonials of actual breast cancer survivors. These testimonials will include story-like details of what these survivors find enjoyable about exercising and what they have done to make exercise enjoyable.
Study: NCT01923480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15% CLINISOL - Sulfite-free (Amino Acid) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15% CLINISOL - Sulfite-free (Amino Acid) Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15% CLINISOL - Sulfite-free (Amino Acid) Injection
Study: NCT03169894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDGN-002
Description: MDGN-002 is a fully human IgG4 monoclonal antibody specific to human LIGHT.
Study: NCT01740531

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S-303 Treated Red Blood Cells (RBCs)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional, untreated Red Blood Cells
Study: NCT02903199

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein
Description: Whey protein (18 g) administered immediately prior to breakfast and lunch meals.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolysed Protein
Description: Hydrolysed whey protein (19.1 g) administered immediately prior to breakfast and lunch meals.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intervention administered immediately prior to breakfast and lunch meals.
Study: NCT01871675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study: NCT02085213

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: Matched placebo
Study: NCT00370240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhydrate de Ropivacaine
Description: The Ropivacaïne group received 3mg/kg of 0.375% ropivacaïne(0.75% ropivacaïne, Astra, mixed with saline)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The PCB group received saline solution in equal volume.
Study: NCT03357913

Intervention type: OTHER
Intervention: Lung transplantation
Description: To estimate the incidence of non-respiratory co-morbidities after lung transplantation between 2004 and 2014 in the cohort of patients with cystic fibrosis grafted in the Rhône-Alpes region
Study: NCT02368080

Intervention type: DEVICE
Intervention: Comparison of two MBWN2 devices : EasyOne Pro Lab versus Exhalyzer D
Description: Healthy and Cystic Fibrosis participants will perform the same day MBWN2 tests in duplicate with each device.

Intervention type: DEVICE
Intervention: Comparison of two MBWN2 devices : EasyOne Pro Lab versus Exhalyzer D
Description: Healthy and Cystic Fibrosis participants will perform the same day MBWN2 tests in duplicate with each device.
Study: NCT04115618

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Simultaneous integrated boost intensity-modulated chemoradiotherapy
Description: Using IMRT technology, two fields are irradiated synchronously, prescription radiation dose: 50.4 Gy/28F in PTV-C, 1.8 Gy per fraction; 63 Gy/28F in PTV-G, 2.25 Gy per fraction. Six times of concurrent DP week regimen chemotherapy: cisplatin 20mg/m2 qw plus docetaxel 20mg/m2 qw.
Study: NCT03620812

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: rapeseed or soy protein or no protein
Description: 25g rapeseed protein in comparison to 25g soy protein or no protein - dosage of 25 g per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: rapeseed or soy protein or no protein
Description: 25g rapeseed protein in comparison to 25g soy protein or no protein - dosage of 25 g per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: rapeseed or soy protein or no protein
Description: 25g rapeseed protein in comparison to 25g soy protein or no protein - dosage of 25 g per day
Study: NCT04218799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Mupirocin and Topical Chlorhexidine
Description: Antimicrobial antiseptic skin cleanser (4% chlorhexidine) for daily use on Day 1, 3 and 5 of Week 8 of the study. BACTROBAN NASAL ointment (mupirocin calcium ointment, 2%) for use intranasally twice-daily on Day 1, 2, 3, 4 and 5 of Week 8 of the study.
Study: NCT02086721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19-IL2
Description: Patients receive a schedule of 1 x 30 Gy, 3 x 15-20 Gy; 5 x 12 Gy; 8 x 7.5 Gy; to the 80 % or 100 % isodose.~Step -1: Toxicity of 10 Mio IU of L19-IL2 (n=3-6)10 Mio IU of L19-IL2 (max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21. Step 1: Toxicity of 15 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.~Step 2: Toxicity of 22.5 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle.~Step 3: Expansion cohort of the maximally tolerable dose (n=10) Administration of the maximally tolerable dose of L19-IL2(max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle.
Study: NCT02308176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APP + health advice
Description: health advice and reinforcement to it

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: health advice
Description: health advice
Study: NCT01238406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD-logic Artificial Pancreas (MDLAP)
Description: Treatment with the closed loop MD-logic Artificial Pancreas(MDLAP)System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment with insulin pump
Description: Standard treatment with sensor augmented pump therapy
Study: NCT03126916

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study: NCT00426556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus (RAD001) was supplied as tablets in 3 different dosage strengths, 2.5, 5, and 10 mg. The drug was packaged in blisters containing 10 tablets per blister. Blisters and packaging labels were compliant with local regulations and were printed in local language.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus (RAD001) was supplied as tablets in 3 different dosage strengths, 2.5, 5, and 10 mg. The drug was packaged in blisters containing 10 tablets per blister. Blisters and packaging labels were compliant with local regulations and were printed in local language.
Study: NCT03126916

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard of care surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard of care surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard of care surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard of care surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard of care surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV
Study: NCT01986010

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160 High Dose plus MAPA 225 µg /dose IM
Description: V160 plus MAPA administered as a 0.75 mL intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160 High Dose plus MAPA 225 µg /dose IM
Description: V160 plus MAPA administered as a 0.75 mL intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160 Maximum Dose IM
Description: V160 administered as a 0.75 mL intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160 Maximum Dose IM
Description: V160 administered as a 0.75 mL intramuscular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IM
Description: Placebo administered as a 0.75 mL intramuscular injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IM
Description: Placebo administered as a 0.75 mL intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160 Medium Dose ID
Description: V160 administered as a 0.1 mL intradermal injection
Study: NCT03126916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT03533010

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ca500mg
Description: subjects receive a daily dose of 500mg elemental calcium

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VitD800IU
Description: subjects receive a daily dose of 800IU VitD3

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subjects receive placebo tablet
Study: NCT04276025

Intervention type: OTHER
Intervention: Clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome
Description: Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.

Intervention type: OTHER
Intervention: Clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome
Description: Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.

Intervention type: OTHER
Intervention: Clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome
Description: Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
Study: NCT00560300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 alpha D2
Description: Vitamin D sterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 alpha D2
Description: Vitamin D sterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1,25 dihydroxy vitamin D3
Description: Active vitamin D sterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1,25 dihydroxy vitamin D3
Description: Active vitamin D sterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer HCl
Description: Phosphate binder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer HCl
Description: Phosphate binder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Phosphate binder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Phosphate binder
Study: NCT01328743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention
Description: 3 sessions of individual face-to-face counseling at baseline, 3 and 6 months. Sessions are motivationally focused including discussion of pros and cons of drinking and feedback on health and its relation to heavy drinking
Study: NCT03334006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentaglobin®/Standard of Care
Description: Standard of Care treatment + Pentaglobin®
Study: NCT02525926

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: denervation
Description: The examination proceeds under rigorous aseptic technique. Femoral, jugular or brachial venous access will be performed. A flexible catheter is first introduced across a 7-Fr venous introducer, and passed through the right heart chambers toward the origin of the pulmonary arteries. The pressures in the right heart chambers and the pulmonary artery will be measured. At the end of the examination, the catheter is removed, a dressing is applied and the venous puncture is compressed by hand.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham procedure
Description: Right heart catheterism is mandatory in PAH patients care (for diagnosis and during follow-up) and will serve as a  sham  procedure. A usually performed and after a venous punction, cardiac outpout and pulmonary artery pressures will be recorded.~Acoustically isolated headphones will be given to patients during the procedure in order to assure simple-blind during the study.
Study: NCT04097821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg tablets for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg tablets for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg tablets for oral use
Study: NCT01871675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Study: NCT03384238

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence Imaging
Description: Undergo fluorescence imaging

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV
Study: NCT04097821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg tablets for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg tablets for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg tablets for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg tablets for oral use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib
Description: 5 mg tablets for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg tablets for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg tablets for oral use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib
Description: 5 mg tablets for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siremadlin
Description: 10 mg, 20 mg, or 40 mg capsules for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siremadlin
Description: 10 mg, 20 mg, or 40 mg capsules for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizanlizumab
Description: 100 mg/mL concentrate for infusion for intravenous use
Study: NCT00426556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Commercially-available paclitaxel was used in this study. Paclitaxel infusion was administered on Days 1, 8, and 15 of each 28-day cycle, after administration of trastuzumab. Paclitaxel (80 mg/m2) was administered as a 60-minute continuous IV infusion after standard premedication. Patients received paclitaxel for 6 cycles. At the investigator's discretion, treatment with paclitaxel could continue beyond 6 cycles.
Study: NCT02650791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study: NCT04097821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizanlizumab
Description: 100 mg/mL concentrate for infusion for intravenous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sabatolimab
Description: 100 mg/mL or 400 mg/4 mL concentrate for infusion for intravenous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sabatolimab
Description: 100 mg/mL or 400 mg/4 mL concentrate for infusion for intravenous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rineterkib
Description: 100 mg capsule for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rineterkib
Description: 100 mg capsule for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIS793
Description: 700 mg/7 mL concentrate for intravenous use
Study: NCT03384238

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV
Study: NCT04097821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIS793
Description: 700 mg/7 mL concentrate for intravenous use
Study: NCT03442348

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid
Description: Participants in the bottom median of dietary fibre intake (\<15 g per day) will be randomised into one of two arms. Participants in the second arm (N\>32) will be required to take one 500mg capsule of Omega 3 along with a meal daily for 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin fibre
Description: The participants in the control arm (N\>32) will be asked to take 20 g of fibre (resistant starch + inulin) per day that are known favour production of SCFAs in the colon for a period of 6 weeks. The inulin powder will be provided in pre-weighed sachets containing 10g each which can be taken mixed in water or a suitable beverage of choice taken twice (morning and evening) per day.
Study: NCT02683304

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma S100B levels at inclusion
Description: Patients will have blood drawn to measure plasma S100B levels at inclusion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: If not performed under emergency conditions, patients will have an MRI on days 2-4.
Study: NCT01986010

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160 Medium Dose ID
Description: V160 administered as a 0.1 mL intradermal injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ID
Description: Placebo administered as a 0.1 mL intradermal injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ID
Description: Placebo administered as a 0.1 mL intradermal injection